AV-RENEW | 20 mg Vial
$140.00
Support
Purity & Quality
Within 24 Hours
Canada’s only domestic peptide manufacturer. Ships to every province and territory.
AV-RENEW combines two synthetic research peptides, BPC-157 and TB-500, in a single 20 mg vial. The formulation contains a listed 10 mg of each peptide, supplied together as lyophilized (freeze-dried) powder for laboratory research.
- A sealed vial containing 20 mg of lyophilized (freeze-dried) peptide blend.
- Not included: Laboratory preparation materials and accessories.
Description
AV-RENEW: BPC-157 + TB-500 Research Peptide Blend
AV-RENEW is a two-peptide research formulation combining BPC-157 and TB-500 in one sealed vial. Each vial contains a listed 10 mg of BPC-157 and 10 mg of TB-500, for a total of 20 mg of lyophilized powder.
Although frequently paired in commercial research blends, BPC-157 and TB-500 are structurally unrelated synthetic peptides with distinct scientific backgrounds. Both have been investigated individually in experimental research, while published studies examining their combined formulation remain limited.
Understanding the Two Research Peptides
BPC-157 is a synthetic peptide consisting of 15 amino acid residues. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val.
BPC-157 was characterized as a 15-amino-acid fragment associated with BPC, a substance originally isolated from gastric juice and described by its discoverers as having a molecular size of approximately 40,000 Da.
TB-500 is associated with thymosin β4, an actin-binding protein consisting of 43 amino acid residues. The designation TB-500 is not always used consistently across research materials and commercial products.
PubChem identifies TB-500 as Ac-LKKTETQ, the N-acetylated 17–23 fragment of thymosin β4. This seven-residue fragment has a molecular mass of approximately 889.0 g/mol.
The name is also used in reference to full-length thymosin β4, a 43-residue protein with a molecular mass of approximately 4963 g/mol. These are chemically distinct materials, making confirmation of the supplied peptide’s identity important for laboratory research.
In 2012, researchers at a Belgian doping-control laboratory identified the acetylated fragment Ac-LKKTETQ in a product marketed as TB-500.
Published Research on the BPC-157 + TB-500 Combination
While individual research involving BPC-157 and thymosin β4-related peptides spans multiple publications, studies specifically examining BPC-157 and TB-500 together are comparatively limited.
A PubMed search conducted on October 16, 2026, for publications naming BPC-157 alongside TB-500 or thymosin β4 returned only a small number of records, most of which were reviews.
View the combined-peptide PubMed literature search
2026 Exploratory Animal Research
One controlled animal study identified in the supplied research literature examined BPC-157 and TB-500 individually and in combination using a surgically repaired Achilles tendon model in rats.
- Subjects: 32 rats with surgically cut and repaired Achilles tendons.
- Groups: Four groups of eight animals each.
- Comparisons: Control, BPC-157, TB-500 and combined BPC-157 + TB-500.
- Assessments: Tendon load to failure and histological examination at four weeks.
The authors described the investigation as exploratory. The findings represent one study conducted in one rat model and should not be generalized to other experimental settings, species or clinical applications.
View Biçer et al. (2026) on PubMed
Formulation and Laboratory Considerations
AV-RENEW combines the two listed peptides into one freeze-dried preparation rather than supplying them in separate vials.
The stated 20 mg total consists of 10 mg BPC-157 and 10 mg TB-500. These quantities describe the listed formulation and do not independently establish the identity, purity or exact composition of a particular production lot.
Molecular formulas, peptide sequences and molecular weights referenced in the product specifications are published chemical reference values. Confirmation of actual supplied materials requires appropriate batch-specific analytical documentation, particularly given the naming ambiguity associated with TB-500.
All peptides are intended exclusively for nonclinical laboratory research. Not for human consumption or veterinary use. Aevigenix does not accept liability for misuse.
AV-RENEW: BPC-157 + TB-500 Research Peptide Blend
AV-RENEW is a two-peptide research formulation combining BPC-157 and TB-500 in one sealed vial. Each vial contains a listed 10 mg of BPC-157 and 10 mg of TB-500, for a total of 20 mg of lyophilized powder.
Although frequently paired in commercial research blends, BPC-157 and TB-500 are structurally unrelated synthetic peptides with distinct scientific backgrounds. Both have been investigated individually in experimental research, while published studies examining their combined formulation remain limited.
Understanding the Two Research Peptides
BPC-157 is a synthetic peptide consisting of 15 amino acid residues. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val.
BPC-157 was characterized as a 15-amino-acid fragment associated with BPC, a substance originally isolated from gastric juice and described by its discoverers as having a molecular size of approximately 40,000 Da.
TB-500 is associated with thymosin β4, an actin-binding protein consisting of 43 amino acid residues. The designation TB-500 is not always used consistently across research materials and commercial products.
PubChem identifies TB-500 as Ac-LKKTETQ, the N-acetylated 17–23 fragment of thymosin β4. This seven-residue fragment has a molecular mass of approximately 889.0 g/mol.
The name is also used in reference to full-length thymosin β4, a 43-residue protein with a molecular mass of approximately 4963 g/mol. These are chemically distinct materials, making confirmation of the supplied peptide's identity important for laboratory research.
In 2012, researchers at a Belgian doping-control laboratory identified the acetylated fragment Ac-LKKTETQ in a product marketed as TB-500.
Published Research on the BPC-157 + TB-500 Combination
While individual research involving BPC-157 and thymosin β4-related peptides spans multiple publications, studies specifically examining BPC-157 and TB-500 together are comparatively limited.
A PubMed search conducted on October 16, 2026, for publications naming BPC-157 alongside TB-500 or thymosin β4 returned only a small number of records, most of which were reviews.
View the combined-peptide PubMed literature search
2026 Exploratory Animal Research
One controlled animal study identified in the supplied research literature examined BPC-157 and TB-500 individually and in combination using a surgically repaired Achilles tendon model in rats.
- Subjects: 32 rats with surgically cut and repaired Achilles tendons.
- Groups: Four groups of eight animals each.
- Comparisons: Control, BPC-157, TB-500 and combined BPC-157 + TB-500.
- Assessments: Tendon load to failure and histological examination at four weeks.
The authors described the investigation as exploratory. The findings represent one study conducted in one rat model and should not be generalized to other experimental settings, species or clinical applications.
View Biçer et al. (2026) on PubMed
Formulation and Laboratory Considerations
AV-RENEW combines the two listed peptides into one freeze-dried preparation rather than supplying them in separate vials.
The stated 20 mg total consists of 10 mg BPC-157 and 10 mg TB-500. These quantities describe the listed formulation and do not independently establish the identity, purity or exact composition of a particular production lot.
Molecular formulas, peptide sequences and molecular weights referenced in the product specifications are published chemical reference values. Confirmation of actual supplied materials requires appropriate batch-specific analytical documentation, particularly given the naming ambiguity associated with TB-500.
All peptides are intended exclusively for nonclinical laboratory research. Not for human consumption or veterinary use. Aevigenix does not accept liability for misuse.
View Full Terms of Use-
New
AV-FOREVER | 50 mg Vial
$150.00 -
New
AV-RESTORE | 5 mg Vial
$69.50 -
New
AV-SHIELD | 10 mg Vial
$150.00
